FOXO4-DRI (10 mg Vial) Dosage Protocol
FOXO4-DRI is a synthetic senolytic peptide that disrupts the FOXO4-p53 interaction, selectively triggering apoptosis in senescent cells while sparing healthy ones.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg | 7.5 units (0.075 mL) |
| Weeks 5–8 | 375 mcg | 11 units (0.11 mL) |
| Weeks 9–12 | 500 mcg | 15 units (0.15 mL) |
| Weeks 13–16 | 500 mcg | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the standard 3.0 mL dilution to maintain injection volumes under 0.2 mL for all doses. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (FOXO4-DRI, 10 mg each) | 8 weeks ≈ 3 vials 12 weeks ≈ 4 vials 16 weeks ≈ 5 vials |
| Insulin Syringes (U-100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100-count boxes 12 weeks: 168 swabs → recommend 2 × 100-count boxes 16 weeks: 224 swabs → recommend 3 × 100-count boxes |
Protocol Overview
The mechanism (selective senescent-cell apoptosis) does not require continuous administration; once senescent cells are cleared, the body needs time to fully process the changes. Limited human clinical data — most evidence is preclinical mouse studies.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
FOXO4-DRI is a D-retro-inverso peptide that disrupts the FOXO4-p53 protein interaction. In senescent cells (which accumulate with age and contribute to tissue dysfunction), this interaction sequesters p53 and prevents apoptosis. Disrupting the interaction releases p53 to drive selective senescent-cell apoptosis.
Healthy cells lack the FOXO4-p53 dependency and are spared. Animal studies show improved organ function, hair regrowth, and physical performance after senolytic dosing in aged mice.
Potential Benefits & Side Effects
Potential Benefits
- Selective senescent-cell apoptosis.
- Improvements in physical performance in aged mice.
- Hair regrowth and improved kidney function in aged-mouse studies.
- Cycled dosing — does not require continuous administration.
Side Effect Profile
- Limited human safety data.
- Injection-site reactions possible.
- Theoretical concerns with rapid senescent-cell clearance in patients with high senescent burden.
Lifestyle Factors
- Cycled dosing (3×/week × 3 weeks, then break) is standard.
- Pair with anti-inflammatory and longevity-supportive lifestyle.
Injection Technique
- Subcutaneous, rotate sites.